Stocks · News reference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Savara Inc. has released new data demonstrating the treatment effects of its molgramostim inhalation solution in patients with autoimmune pulmonary alveolar proteinosis (aPAP) who exhibit mild diffusion impairment.
JP Morgan analyst Caroline Pocher initiates coverage on Savara (NASDAQ:SVRA) with a Overweight rating and announces Price Target of $12.
U.S. stocks fell, while BKV surged 9.2% on an equipment contract announcement; Penguin Solutions led gainers with a 16.3% jump on strong results.